Your session is about to expire
← Back to Search
Immunotherapy + Radiation for Advanced Lung or Liver Cancer
Study Summary
This trial is testing the side effects and best dose of an immunotherapy drug when given with another immunotherapy drug and/or radiation therapy. The immunotherapy drugs may help the body's immune system attack the cancer, and the radiation therapy may kill cancer cells.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2017 Phase 3 trial • 1289 Patients • NCT01285609Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I've waited the required time after my last cancer treatment to join this study.My liver function tests are within normal limits without needing treatments to achieve this.I do not have any health or mental conditions that could make the study unsafe for me.I have not had a bad reaction to previous immunotherapy treatments.I have had cancer treatment before with immunotherapy and my cancer still got worse.My platelet count is at least 75,000 without recent medical help.I am not pregnant or planning to become pregnant/breastfeed during and after the study. I agree to follow strict birth control measures.My doctor may allow me to have radiation again in areas previously treated.I do not have any severe illnesses or social situations that would stop me from following the study's requirements.I am not on treatments like IL-2, interferon, chemotherapy, or high-dose steroids while receiving ipilimumab.I have had a stem cell transplant from a donor.I can take care of myself but might not be able to do heavy physical work.My cancer has spread to my liver or lungs, confirmed by a biopsy.I have a cancer lesion in my lung/chest or liver that can be treated with SBRT.My hemoglobin level is at least 9 g/dL without recent transfusions or growth factors.My total bilirubin level is 2.0 mg/dL or less, and I don't have Gilbert's syndrome.My HIV, hepatitis B, or hepatitis C is not stable.My creatinine levels are within twice the normal upper limit without using growth factors or transfusions in the last 2 weeks.My white blood cell count is high enough without recent medical help.I have a current diagnosis of diverticulitis or other serious GI conditions.I haven't had vaccines for infectious diseases a month before or after ipilimumab.I have brain metastases but no symptoms, and I haven't taken high doses of steroids recently.
- Group 1: Group I (ipilimumab, BMS-986156, nivolumab)
- Group 2: Group II (ipilimumab, BMS-986156, SBRT, nivolumab)
- Group 3: Group III (nivolumab, BMS-986156, SBRT)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What are the chief aims of this experiment?
"The primary objective of the study, assessed for up to a year, is examining adverse events related with nivolumab alongside BMS-986156 and SBRT targeting lung lesions. Additionally, secondary objectives include evaluating if skeletal mass, neutrophil count and ratio, and tumor bulk are linked to clinical outcomes or adverse events via qualitative correlations; exploring how tumor kinetics in combination with other data can be used to determine treatment response through mathematical modelling; as well as determining whether increased tumour mutational burden leads to improved clinical responses."
What is the highest number of participants this experiment can accommodate?
"Affirmative. The information on clinicaltrials.gov states that the medical trial, which was first posted 19th August 2019, is actively recruiting. Approximately 60 participants must be recruited from one location."
Are there any other empirical investigations that have utilized Ipilimumab?
"Currently, 765 clinical studies seeking to evaluate Ipilimumab are underway. Of those trials, 86 have entered Phase 3 and many of these are situated in Pittsburgh, Pennsylvania. Globally there are 42707 sites conducting research for this treatment option."
Are there any patient slots left available to participate in this trial?
"Correct. Clinicaltrials.gov data indicates that this clinical trial, which was launched on August 19th 2019, is presently running and looking for applicants. Approximately 60 participants are needed from a single centre."
What pathologies has Ipilimumab been found to be an efficacious treatment for?
"Ipilimumab can be a viable option for treating prior anti-angiogenic therapy, malignant neoplasms, and inoperable melanoma."
Share this study with friends
Copy Link
Messenger